Mesenchymal Stem Cells Clinical Trial
Official title:
Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. Our first objective was to evaluate the effect of such treatment on poor graft function, and second object was to investigate the safety of such treatment.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 2016 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 14 Years to 65 Years |
Eligibility |
Inclusion Criteria: - A patient age of 14-65 years - Poor graft function developing after allo-HSCT - Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: - Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) - Patients with any conditions not suitable for the trial (investigators' decision) |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Department of Hematology,Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Nanfang Hospital of Southern Medical University | Guangdong General Hospital, Guangzhou First Municipal People’s Hospital, Guangzhou General Hospital of Guangzhou Military Command, Peking University People's Hospital, Southern Medical University, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Third Affiliated Hospital, Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China |
China,
Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, Dorval C, Martiat P, Lewalle P, Lagneaux L, Bron D. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev. 2009 Nov;18(9):1247-52. doi: 10.1089/scd.2009.0029. — View Citation
Sánchez-Guijo FM, López-Villar O, López-Anglada L, Villarón EM, Muntión S, Díez-Campelo M, Perez-Simón JA, San Miguel JF, Caballero D, del Cañizo MC. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion. 2012 May;52(5):1086-91. doi: 10.1111/j.1537-2995.2011.03400.x. Epub 2011 Oct 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | hematopoietic recovery | Hematopoietic reconstitution post-transplantation is defined as reconstitution of both neutrophil and platelet numbers. Neutrophil reconstitution is defined as occurring on the first 3 consecutive days with an neutrophil(NEU)>0.5×10^9/L, and platelet (PLT) reconstitution is defined as the first >20×10^9/L for 3 consecutive days. | 1 year | No |
Secondary | infections, primary underlying disease relapse and any toxic side effects of MSCs treatment | Infections will be mainly focused within the first 100 days after MSCs treatment. Toxic side effects of treatment includes acute toxicity and late side effects. Acute toxicity principally involves the heart,live and kidney. Late toxic side effects involves principally the development of secondary tumors and relapse of the primary disease. | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01219465 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01221428 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis
|
Phase 1/Phase 2 | |
Completed |
NCT03105284 -
Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction
|
N/A | |
Not yet recruiting |
NCT01224327 -
Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06149832 -
Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing
|
Phase 4 | |
Recruiting |
NCT05165459 -
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
|
N/A | |
Active, not recruiting |
NCT04014166 -
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Completed |
NCT00956891 -
Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT01218464 -
Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Recruiting |
NCT00953485 -
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04863183 -
Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT06360861 -
Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT05018754 -
Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
|
||
Recruiting |
NCT04356287 -
Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03130374 -
Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02673788 -
Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage
|
||
Recruiting |
NCT01763099 -
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
|
Phase 2 | |
Completed |
NCT02302599 -
Mesenchymal Stem Cells to Treat Type 2 Diabetes
|
Phase 2 |